{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T14:19:31Z","timestamp":1793110771153,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T00:00:00Z","timestamp":1466121600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Atheroscler Rep"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s11883-016-0604-3","type":"journal-article","created":{"date-parts":[[2016,6,17]],"date-time":"2016-06-17T03:47:04Z","timestamp":1466135224000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":63,"title":["Statins and Their Effect on PCSK9\u2014Impact and Clinical Relevance"],"prefix":"10.1007","volume":"18","author":[{"given":"Beth A.","family":"Taylor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,6,17]]},"reference":[{"key":"604_CR1","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","volume":"279","author":"JR Downs","year":"1998","unstructured":"Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615\u201322.","journal-title":"JAMA"},{"key":"604_CR2","first-page":"1383","volume":"344","author":"4S Study Group","year":"1994","unstructured":"4S Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383\u20139.","journal-title":"Lancet"},{"key":"604_CR3","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.numecd.2014.05.009","volume":"24","author":"Z Reiner","year":"2014","unstructured":"Reiner Z. Resistance and intolerance to statins. Nutr Metab Cardiovasc Dis. 2014;24:1057\u201366.","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"604_CR4","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0021-9150(95)05571-D","volume":"117","author":"F Pazzucconi","year":"1995","unstructured":"Pazzucconi F, Dorigotti F, Gianfranceschi G, Campagnoli G, Sirtori M, Franceschini G, et al. Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity. Atherosclerosis. 1995;117:189\u201398.","journal-title":"Atherosclerosis"},{"key":"604_CR5","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1177\/1826186807003001-202","volume":"3","author":"S Nodari","year":"2007","unstructured":"Nodari S, Rocca P, Saporetti A, Bettari L, Foresti AL, Tanghetti E, et al. The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia. Heart Int. 2007;3:12.","journal-title":"Heart Int"},{"key":"604_CR6","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","volume":"19","author":"E Bruckert","year":"2005","unstructured":"Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study. Cardiovasc Drugs Ther. 2005;19:403\u201314.","journal-title":"Cardiovasc Drugs Ther"},{"key":"604_CR7","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","volume":"127","author":"BA Parker","year":"2013","unstructured":"Parker BA, Capizzi JA, Grimaldi AS, Clarkson PM, Cole SM, Keadle J, et al. Effect of statins on skeletal muscle function. Circulation. 2013;127:96\u2013103.","journal-title":"Circulation"},{"key":"604_CR8","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jacl.2013.03.001","volume":"7","author":"MY Wei","year":"2013","unstructured":"Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7:472\u201383.","journal-title":"J Clin Lipidol"},{"key":"604_CR9","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1002\/pds.3787","volume":"24","author":"JM Franklin","year":"2015","unstructured":"Franklin JM, Krumme AA, Tong AY, Shrank WH, Matlin OS, Brennan TA, et al. Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiol Drug Saf. 2015;24:1105\u201313. This publication established that patients consistently using statin therapy were less likely to experience cardiovascular events over a 12 month period.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"604_CR10","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/j.amjcard.2011.01.052","volume":"107","author":"DG Pittman","year":"2011","unstructured":"Pittman DG, Chen W, Bowlin SJ, Foody JM. Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations. Am J Cardiol. 2011;107:1662\u20136.","journal-title":"Am J Cardiol"},{"key":"604_CR11","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","volume":"32","author":"JD Horton","year":"2007","unstructured":"Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32:71\u20137.","journal-title":"Trends Biochem Sci"},{"key":"604_CR12","first-page":"774","volume":"373","author":"MS Sabatine","year":"2015","unstructured":"Sabatine MS, Wasserman SM, Stein EA. PCSK9 inhibitors and cardiovascular events. N Engl J Med. 2015;373:774\u20135.","journal-title":"N Engl J Med"},{"key":"604_CR13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.amjcard.2013.01.289","volume":"111","author":"T Nozue","year":"2013","unstructured":"Nozue T, Hattori H, Ishihara M, Iwasaki T, Hirano T, Kawashiri MA, et al. Comparison of effects of pitavastatin versus pravastatin on serum proprotein convertase subtilisin\/kexin type 9 levels in statin-naive patients with coronary artery disease. Am J Cardiol. 2013;111:1415\u20139.","journal-title":"Am J Cardiol"},{"key":"604_CR14","doi-asserted-by":"crossref","unstructured":"Ridker PM, Mora S, Rose L, JUPITER Trial Study Group. Per cent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents. Eur Heart J. 2016. This analysis of data from the JUPITER data established the heterogeneity in LDL-C response with a single-dose statin and demonstrated that 11% of patients exhibit no reduction in LDL-C.","DOI":"10.1093\/eurheartj\/ehw046"},{"key":"604_CR15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","volume":"34","author":"M Abifadel","year":"2003","unstructured":"Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003;34:154\u20136.","journal-title":"Nat Genet"},{"key":"604_CR16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1161\/CIRCGENETICS.108.795013","volume":"1","author":"D Voora","year":"2008","unstructured":"Voora D, Shah SH, Reed CR, Zhai J, Crosslin DR, Messer C, et al. Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response. Circ Cardiovasc Genet. 2008;1:100\u20136.","journal-title":"Circ Cardiovasc Genet"},{"key":"604_CR17","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.cca.2014.01.043","volume":"431","author":"NQ Wu","year":"2014","unstructured":"Wu NQ, Li JJ. PCSK9 gene mutations and low-density lipoprotein cholesterol. Clin Chim Acta. 2014;431:148\u201353.","journal-title":"Clin Chim Acta"},{"key":"604_CR18","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/s12944-015-0154-7","volume":"14","author":"G Cai","year":"2015","unstructured":"Cai G, Zhang B, Shi G, Weng W, Ma C, Song Y, et al. The associations between proprotein convertase subtilisin\/kexin type 9 E670G polymorphism and the risk of coronary artery disease and serum lipid levels: a meta-analysis. Lipids Health Dis. 2015;14:149. This meta-analysis provided strong data the PCSK9 polymorphism associated with a gain-in-function of PCSK9 increases LDL-C levels and cardiovascular disease risk.","journal-title":"Lipids Health Dis"},{"key":"604_CR19","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","volume":"354","author":"JC Cohen","year":"2006","unstructured":"Cohen JC, Boerwinkle E, Mosley Jr TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264\u201372.","journal-title":"N Engl J Med"},{"key":"604_CR20","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5551\/jat.25841","volume":"22","author":"S Li","year":"2015","unstructured":"Li S, Zhu CG, Guo YL, Xu RX, Zhang Y, Sun J, et al. The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. J Atheroscler Thromb. 2015;22:76\u201384.","journal-title":"J Atheroscler Thromb"},{"key":"604_CR21","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1161\/CIRCULATIONAHA.115.018531","volume":"133","author":"K Leander","year":"2016","unstructured":"Leander K, Malarstig A, Van\u2019t Hooft FM, Hyde C, Hellenius ML, Troutt JS, et al. Circulating PCSK9 predicts future risk of cardiovascular events independently of established risk factors. Circulation. 2016;133:1230\u20139. PCSK 9 levels appear to exert an independent influence on cardiovascular risk over a 15 year follow period as higher levels of PCSK9 are associated with greater event risk independent of traditional risk factors including blood lipids.","journal-title":"Circulation"},{"key":"604_CR22","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","volume":"248","author":"JM Cheng","year":"2016","unstructured":"Cheng JM, Oemrawsingh RM, Garcia-Garcia HM, Boersma E, van Geuns RJ, Serruys PW, et al. PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study. Atherosclerosis. 2016;248:117\u201322. PCSK9 levels affect cardiovascular disease risk independently of blood lipid levels and\/or statin through an association with several indices of plaque volume and tissue composition.","journal-title":"Atherosclerosis"},{"key":"604_CR23","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","volume":"64","author":"SM Boekholdt","year":"2014","unstructured":"Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, et al. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. J Am Coll Cardiol. 2014;64:485\u201394.","journal-title":"J Am Coll Cardiol"},{"key":"604_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/tpj.2016.3","author":"Q Feng","year":"2016","unstructured":"Feng Q, Wei WQ, Chung CP, Levinson RT, Bastarache L, Denny JC, et al. The effect of genetic variation in PCSK9 on the LDL-cholesterol response to statin therapy. Pharmacogenomics J. 2016. doi: 10.1038\/tpj.2016.3 . Both gain-of-function and loss-of-function variants in the PCSK9 gene influence the efficacy of statin therapy for lowering LDL-C, demonstrating the interaction between statins and PCSK9 on lipid-lowering and cardiovascular risk.","journal-title":"Pharmacogenomics J"},{"key":"604_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","volume":"5","author":"DI Chasman","year":"2012","unstructured":"Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. Circ Cardiovasc Genet. 2012;5:257\u201364.","journal-title":"Circ Cardiovasc Genet"},{"key":"604_CR26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1161\/CIRCGENETICS.108.818062","volume":"2","author":"JF Thompson","year":"2009","unstructured":"Thompson JF, Hyde CL, Wood LS, Paciga SA, Hinds DA, Cox DR, et al. Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet. 2009;2:173\u201381.","journal-title":"Circ Cardiovasc Genet"},{"key":"604_CR27","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","volume":"26","author":"KE Berge","year":"2006","unstructured":"Berge KE, Ose L, Leren TP. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler Thromb Vasc Biol. 2006;26:1094\u2013100.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"604_CR28","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.atherosclerosis.2007.12.005","volume":"200","author":"E Polisecki","year":"2008","unstructured":"Polisecki E, Peter I, Robertson M, McMahon AD, Ford I, Packard C, et al. Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population. Atherosclerosis. 2008;200:95\u2013101.","journal-title":"Atherosclerosis"},{"key":"604_CR29","doi-asserted-by":"crossref","first-page":"5068","DOI":"10.1038\/ncomms6068","volume":"5","author":"I Postmus","year":"2014","unstructured":"Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5:5068. One of the largest meta-analyses to date did not find a relationship between variants in the PCSK9 gene and the LDL-C response to statin therapy, demonstrating that there are likely other modulators of the PCSK9-statin effect on LDL-C.","journal-title":"Nat Commun"},{"key":"604_CR30","doi-asserted-by":"crossref","first-page":"140723","DOI":"10.1155\/2014\/140723","volume":"2014","author":"BA Taylor","year":"2014","unstructured":"Taylor BA, Panza G, Pescatello LS, Chipkin S, Gipe D, Shao W, et al. Serum PCSK9 levels distinguish individuals who do not respond to high-dose statin therapy with the expected reduction in LDL-C. J Lipids. 2014;2014:140723. PCSK levels may be higher at baseline in individuals who do not respond to high-dose atorvastatin with the expected reduction in LDL-C, supporting that PCSK9 levels influence the magnitude of the statin response.","journal-title":"J Lipids"},{"key":"604_CR31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1194\/jlr.M700443-JLR200","volume":"49","author":"HJ Jeong","year":"2008","unstructured":"Jeong HJ, Lee HS, Kim KS, Kim YK, Yoon D, Park SW. Sterol-dependent regulation of proprotein convertase subtilisin\/kexin type 9 expression by sterol-regulatory element binding protein-2. J Lipid Res. 2008;49:399\u2013409.","journal-title":"J Lipid Res"},{"key":"604_CR32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0060095","volume":"8","author":"HK Berthold","year":"2013","unstructured":"Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I. Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One. 2013;8, e60095.","journal-title":"PLoS One"},{"key":"604_CR33","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/dom.12536","volume":"17","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar A, Simental-Mendia LE, Guerrero-Romero F, Golledge J, Watts GF. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials. Diabetes Obes Metab. 2015;17:1042\u201355. This review uses data from 15 statin clinical trials to establish that statin therapy increases plasma PCSK9 levels.","journal-title":"Diabetes Obes Metab"},{"key":"604_CR34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1194\/jlr.M700437-JLR200","volume":"49","author":"HE Careskey","year":"2008","unstructured":"Careskey HE, Davis RA, Alborn WE, Troutt JS, Cao G, Konrad RJ. Atorvastatin increases human serum levels of proprotein convertase subtilisin\/kexin type 9. J Lipid Res. 2008;49:394\u20138.","journal-title":"J Lipid Res"},{"key":"604_CR35","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1194\/jlr.M900273-JLR200","volume":"51","author":"G Dubuc","year":"2010","unstructured":"Dubuc G, Tremblay M, Pare G, Jacques H, Hamelin J, Benjannet S, et al. A new method for measurement of total plasma PCSK9: clinical applications. J Lipid Res. 2010;51:140\u20139.","journal-title":"J Lipid Res"},{"key":"604_CR36","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CRD.0000000000000025","volume":"22","author":"A Sahebkar","year":"2014","unstructured":"Sahebkar A. Circulating levels of proprotein convertase subtilisin kexin type 9 are elevated by fibrate therapy: a systematic review and meta-analysis of clinical trials. Cardiol Rev. 2014;22:306\u201312.","journal-title":"Cardiol Rev"},{"key":"604_CR37","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.atherosclerosis.2010.05.027","volume":"212","author":"P Costet","year":"2010","unstructured":"Costet P, Hoffmann MM, Cariou B, Guyomarc\u2019h Delasalle B, Konrad T, Winkler K. Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis. 2010;212:246\u201351.","journal-title":"Atherosclerosis"},{"key":"604_CR38","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.amjcard.2014.10.018","volume":"115","author":"AV Khera","year":"2015","unstructured":"Khera AV, Qamar A, Reilly MP, Dunbar RL, Rader DJ. Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin\/kexin type 9 levels in patients with dyslipidemia. Am J Cardiol. 2015;115:178\u201382. This series of studies establishes that multiple lipid-lowering therapies alone and in combination influence PCSK9 levels, demonstrating that statin therapy is not the only therapy to effect plasma PCSK9 and the LDL-C response to therapy.","journal-title":"Am J Cardiol"},{"key":"604_CR39","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s12916-015-0358-8","volume":"13","author":"XL Zhang","year":"2015","unstructured":"Zhang XL, Zhu QQ, Zhu L, Chen JZ, Chen QH, Li GN, et al. Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 2015;13:123 015-0358-8.","journal-title":"BMC Med"},{"key":"604_CR40","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1001\/jama.2012.25790","volume":"308","author":"D Sullivan","year":"2012","unstructured":"Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012;308:2497\u2013506.","journal-title":"JAMA"},{"key":"604_CR41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","volume":"37","author":"MJ Lipinski","year":"2016","unstructured":"Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur Heart J. 2016;37:536\u201345. This meta-analysis of 17 trials involving PCSK9 inhibitors confirmed individual trial evidence that PCSK9 inhibitors are effective drugs for reducing LDL-C and PCSK9.","journal-title":"Eur Heart J"}],"container-title":["Current Atherosclerosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0604-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11883-016-0604-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11883-016-0604-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,9]],"date-time":"2019-09-09T17:38:14Z","timestamp":1568050694000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11883-016-0604-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,17]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["604"],"URL":"https:\/\/doi.org\/10.1007\/s11883-016-0604-3","relation":{},"ISSN":["1523-3804","1534-6242"],"issn-type":[{"value":"1523-3804","type":"print"},{"value":"1534-6242","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,17]]},"article-number":"46"}}